Loading organizations...
Phase Genomics has raised $3.0M across 1 funding round.
Key people at Phase Genomics.
Phase Genomics has raised $3.0M in total across 1 funding round.
Phase Genomics delivers ultra-long-range genome sequencing technology and bioinformatics for advanced genomic analysis. The company provides proximity ligation kits and Hi-C sequencing methods, crucial for elucidating three-dimensional genome and metagenome structure. Their platform equips researchers to assemble complex genomes and uncover deeper biological insights, enhancing the study of complex biological systems.
Co-founded by biologist Ivan Liachko and software expert Shawn Sullivan, Phase Genomics was established mid-2010s. Liachko's scientific expertise and Sullivan's software background from Microsoft provided a strong foundation. Their insight centered on leveraging higher-order DNA structure to revolutionize genome assembly and expand genetic research capabilities, addressing previous limitations in genomic understanding.
Researchers in human health, agriculture, and environmental biology are primary users of Phase Genomics' products. The company’s mission is to empower professionals with robust genomic tools, accelerating significant scientific discoveries. Phase Genomics envisions making complex biological questions accessible, ultimately fostering advancements tackling global challenges and driving future innovation in life sciences.
Phase Genomics has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2023 | $3M Seed | — | Pack Ventures, Sapphire Ventures, Thomson Reuters Ventures, Tribe Capital | Announced |
Key people at Phase Genomics.
Phase Genomics has raised $3.0M in total across 1 funding round.
Phase Genomics's investors include Pack Ventures, Sapphire Ventures, Thomson Reuters Ventures, Tribe Capital.
Phase Genomics is a Seattle-based biotechnology company founded in 2015, specializing in ultra-long-range genome sequencing solutions using proprietary proximity ligation technology like Hi-C.[1][2][3] It offers laboratory products such as biochemistry kits for plants, animals, microbes, and human samples, alongside SaaS platforms for genome assembly, metagenomic deconvolution, structural variation analysis, and next-generation cytogenetics, serving scientists, clinicians, and researchers in precision oncology, genetic diseases, metagenomics, and plant/animal genomics.[1][2][3] The company solves challenges in identifying genomic abnormalities—such as chromosome-scale rearrangements in cancer or diseases—by replacing outdated methods like karyotyping with faster, more accurate tools that reveal 3D spatial relationships in DNA, accelerating R&D and enabling breakthroughs in diagnostics like acute myeloid leukemia risk stratification.[1][3]
Growth momentum includes awards like Metagenomics Innovation of the Year 2023, new funding for AI-based cancer diagnostics, and advancements like the OncoTerra platform on the Element AVITI sequencing system, positioning it as an innovator in cytogenomics and public health applications.[2][5][7]
Phase Genomics was founded in 2015 in Seattle, Washington, by a team of genome scientists, software engineers, and entrepreneurs who combined expertise in biochemistry and computation to pioneer proximity ligation technology.[1][2] The core idea emerged from Hi-C techniques, which "glue" physically proximate DNA fragments in intact cells for ultra-long-range sequencing, addressing limitations in short-read sequencing for complex genome assembly and structural analysis.[1][3] Early traction came from developing kits and software for diverse samples, evolving into clinical applications like cancer diagnostics where abnormal chromosome junctions reveal disease-causing mutations, marking a pivot from research tools to precision medicine.[1][7]
Key leaders include the Co-Founder & CEO, COO, and Chief Business Officer, driving expansion into platforms like ProxiMeta for metagenomics and CytoTerra for oncology.[2][3]
Phase Genomics rides the wave of ultra-long-range sequencing and AI-driven genomics, capitalizing on next-generation sequencing (NGS) advancements like AVITI to enable rapid, comprehensive genomic profiling beyond short-read limitations.[1][2][3] Timing aligns with surging demand in precision oncology—where structural variants drive 50%+ of cancers—and metagenomics for public health threats like antibiotic resistance or viral outbreaks, amplified by post-pandemic focus on microbiome and cell therapies.[3][5] Market forces favoring it include falling sequencing costs, regulatory pushes for faster diagnostics (e.g., AML stratification), and biotech's shift to multi-omics integration, where Hi-C provides unique 3D insights.[1][7] It influences the ecosystem by democratizing high-fidelity tools for academia, pharma, and clinics, fostering discoveries in functional genomics and bioprospecting while challenging incumbents with scalable SaaS.[3][6]
Phase Genomics is poised to expand its AI-enhanced cytogenomics platforms like OncoTerra into routine clinical use, targeting broader adoption in solid tumors, genetic diseases, and cell therapies amid NGS market growth projected to exceed $20B by 2030.[2][3][7] Trends like multimodal AI for genomic interpretation and metagenomics for personalized medicine will shape its path, potentially through partnerships with sequencer makers or pharma giants. Its influence may evolve from niche innovator to ecosystem leader, driving faster breakthroughs if it scales manufacturing and secures reimbursements for diagnostics—ultimately empowering more scientists to unlock genomics' full potential, as promised since its 2015 origins.[1][3][7]
